About this Research Topic
Despite statins and other therapies, many patients with and without pre-existing cardiovascular disease still suffer from atherosclerotic cardiovascular events. Over the recent decade, novel therapies have been developed to help address this residual risk. Some of these therapies have involved targeting PCSK9 and atherogenic lipoprotein production. Other therapies in development aim at hypertriglyceridemia, elevated lipoprotein(a), and inflammation . This Research Topic will summarize the state-of-the-art of anti-atherosclerotic therapies, the results of cardiovascular outcomes trials, and their implications in reducing cardiovascular disease residual risk.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.